Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world

Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.

Continue reading. 

The lack of a robust, sensitive, and easy-to-use diagnostic test is one of the most serious barriers to the control and prevention of typhoid fever.
Earlier this month, the Coalition against Typhoid (CaT), along with partners at the Bangladesh Pediatric Association, the International Vaccine Institute andthe International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), convened the 8th International Conference on Typhoid Fever and Other Invasive Salmonelloses in Dhaka, Bangladesh. Researchers and health professionals, as well as local, national and international policy makers were in attendance.

Sabin’s Coalition against Typhoid (CaT) Secretariat recently travelled to Atlanta, Georgia for a series of meetings at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).  Typhoid fever is a severe bacterial infection spread through water or food contaminated wit

Vaccine Advocacy and Education

The Vaccine Advocacy and Education program at Sabin is dedicated to reducing the burden of preventable diseases by bringing together key stakeholders and leaders in government, private sector and civil society in order to foster cooperation, share information and best practices, and develop improved vaccine policy and access.

 Over the past year, there have been serious typhoid outbreaks in Indonesia, the Philippines and India. These outbreaks are in addition to the endemic typhoid burden found in throughout Southeast Asia.

Pages

Subscribe to RSS - CaT